Financial reports
10-Q
2022 Q1
Quarterly report
5 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
10-K
2021 FY
Annual report
18 Mar 22
10-Q
2021 Q3
Quarterly report
28 Oct 21
10-Q
2021 Q2
Quarterly report
29 Jul 21
10-Q
2021 Q1
Quarterly report
29 Apr 21
10-K
2020 FY
Annual report
22 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
23 Jul 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
Current reports
8-K
Departure of Directors or Certain Officers
1 Jun 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 22
8-K
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
28 Apr 22
8-K
Genocea Provides Fourth Quarter 2021 Corporate Update
10 Mar 22
8-K
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
7 Mar 22
8-K
Genocea Biosciences Provides Corporate Update
4 Jan 22
8-K
Genocea Provides Third Quarter 2021 Corporate Update
28 Oct 21
8-K
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
13 Sep 21
8-K
Genocea Provides Second Quarter 2021 Corporate Update
29 Jul 21
8-K
Regulation FD Disclosure
13 Jul 21
Registration and prospectus
15-12B
Securities registration termination
13 Jun 22
POS AM
Prospectus update (post-effective amendment)
9 Jun 22
POS AM
Prospectus update (post-effective amendment)
9 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
PRE 14A
Preliminary proxy
14 Apr 21
DEFR14A
Revised proxy
22 May 20
DEFA14A
Additional proxy soliciting materials
20 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
PRE 14A
Preliminary proxy
6 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Mar 19
DEF 14A
Definitive proxy
29 Mar 19
PRE 14A
Preliminary proxy
7 Mar 19
Other
EFFECT
Notice of effectiveness
13 Jun 22
EFFECT
Notice of effectiveness
13 Jun 22
EFFECT
Notice of effectiveness
8 Jun 22
EFFECT
Notice of effectiveness
8 Jun 22
EFFECT
Notice of effectiveness
11 May 21
CORRESP
Correspondence with SEC
6 May 21
UPLOAD
Letter from SEC
5 May 21
EFFECT
Notice of effectiveness
31 Aug 20
CORRESP
Correspondence with SEC
26 Aug 20
UPLOAD
Letter from SEC
26 Aug 20
Ownership
4
Diantha Duvall
3 Jun 22
4
Jessica Baker Flechtner
3 Jun 22
4
William D Clark
3 Jun 22
4
JACQUELYN L SUMER
2 Jun 22
4
William D Clark
2 Jun 22
4
George Siber
1 Jun 22
SC 13D/A
New Enterprise Associates 16, L.P.
27 May 22
4
Paul Edward Walker
26 May 22
4
Peter W. Sonsini
26 May 22
4
SCOTT D SANDELL
26 May 22